Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health. (Q36924692)

From Wikidata

Revision as of 06:01, 21 October 2021 by Edoderoobot (talk | contribs) (‎Changed label, description and/or aliases in nl: nl-description, python code -)

(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)

Jump to navigation Jump to search

scientific article published on 29 August 2007

Language	Label	Description	Also known as
English	Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health.	scientific article published on 29 August 2007

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17761616%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17761616%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

cystic fibrosis

0 references

author name string

Patrick A Flume

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17761616%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

Brian P O'Sullivan

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17761616%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

Karen A Robinson

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17761616%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

Peter J Mogayzel

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17761616%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

Donna Beth Willey-Courand

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17761616%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

Janet Bujan

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17761616%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

Jonathan Finder

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17761616%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

Lynne Quittell

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17761616%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

Randall Rosenblatt

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17761616%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

Robert L Vender

12

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17761616%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

Leslie Hazle

13

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17761616%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

Kathy Sabadosa

14

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17761616%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

Bruce Marshall

15

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17761616%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

Cystic Fibrosis Foundation, Pulmonary Therapies Committee

16

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17761616%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

language of work or name

0 references

publication date

29 August 2007

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17761616%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

American Journal of Respiratory and Critical Care Medicine

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17761616%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

176

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17761616%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17761616%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

957-969

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17761616%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

Consensus conference: practical applications of Pulmozyme. September 22, 1993.

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200705-664OC

21 January 2018

Current methods of the US Preventive Services Task Force: a review of the process

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200705-664OC

21 January 2018

Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis.

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200705-664OC

21 January 2018

Long-term effects of inhaled tobramycin in patients with cystic fibrosis colonized with Pseudomonas aeruginosa.

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200705-664OC

21 January 2018

Efficacy of aerosolized tobramycin in patients with cystic fibrosis.

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200705-664OC

21 January 2018

Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200705-664OC

21 January 2018

Treatment with tobramycin solution for inhalation reduces hospitalizations in young CF subjects with mild lung disease

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200705-664OC

21 January 2018

A randomised clinical trial of nebulised tobramycin or colistin in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200705-664OC

21 January 2018

Dornase alfa as postoperative therapy in cystic fibrosis sinonasal disease

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200705-664OC

21 January 2018

Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200705-664OC

21 January 2018

Dornase alpha and exhaled NO in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200705-664OC

21 January 2018

In vivo effects of recombinant human DNase I on sputum in patients with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200705-664OC

21 January 2018

A two-year randomized, placebo-controlled trial of dornase alfa in young patients with cystic fibrosis with mild lung function abnormalities

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200705-664OC

21 January 2018

Dornase alfa reduces air trapping in children with mild cystic fibrosis lung disease: a quantitative analysis

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200705-664OC

21 January 2018

Use of computerized tomography and chest x-rays in evaluating efficacy of aerosolized recombinant human DNase in cystic fibrosis patients younger than age 5 years: a preliminary study

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200705-664OC

21 January 2018

Mucus clearance and lung function in cystic fibrosis with hypertonic saline

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200705-664OC

21 January 2018

A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200705-664OC

21 January 2018

Short-term efficacy of ultrasonically nebulized hypertonic saline in cystic fibrosis.

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200705-664OC

21 January 2018

Hypertonic saline and recombinant human DNase: a randomised cross-over pilot study in patients with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200705-664OC

21 January 2018

Effects of hypertonic saline, alternate day and daily rhDNase on healthcare use, costs and outcomes in children with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200705-664OC

21 January 2018

Randomised controlled trial of inhaled corticosteroids (fluticasone propionate) in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200705-664OC

21 January 2018

Alternate-day prednisone reduces morbidity and improves pulmonary function in cystic fibrosis.

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200705-664OC

21 January 2018

Interleukin-1 alpha, soluble interleukin-2 receptor, and IgG concentrations in cystic fibrosis treated with prednisolone

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200705-664OC

21 January 2018

Prednisolone in the treatment of airflow obstruction in adults with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200705-664OC

21 January 2018

Effect of high-dose ibuprofen in patients with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200705-664OC

21 January 2018

Effect of ibuprofen on neutrophil migration in vivo in cystic fibrosis and healthy subjects

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200705-664OC

21 January 2018

A pilot study of zafirlukast as an anti-inflammatory agent in the treatment of adults with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200705-664OC

21 January 2018

A double-blind, randomized study of sodium cromoglycate versus placebo in patients with cystic fibrosis and bronchial hyperreactivity

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200705-664OC

21 January 2018

Erythromycin and diffuse panbronchiolitis

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200705-664OC

21 January 2018

Effect of clarithromycin on airway obstruction and inflammatory markers in induced sputum in cystic fibrosis: a pilot study

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200705-664OC

21 January 2018

Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200705-664OC

21 January 2018

Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial.

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200705-664OC

21 January 2018

Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200705-664OC

21 January 2018

Prognosis in cystic fibrosis treated with continuous flucloxacillin from the neonatal period

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200705-664OC

21 January 2018

A placebo-controlled trial of cephalexin therapy in the ambulatory management of patients with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200705-664OC

21 January 2018

Antibiotic prophylaxis in infants and young children with cystic fibrosis: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200705-664OC

21 January 2018

Pulmonary function in infants with cystic fibrosis: the effect of antibiotic treatment

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200705-664OC

21 January 2018

Effectiveness and tolerability of high-dose salmeterol in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200705-664OC

21 January 2018

Bronchodilatory effects of salbutamol, ipratropium bromide, and their combination: double-blind, placebo-controlled crossover study in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200705-664OC

21 January 2018

A placebo-controlled, double-blind trial of the long-term effects of albuterol administration in patients with cystic fibrosis.

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200705-664OC

21 January 2018

Inhaled beta-agonists improve lung function but not maximal exercise capacity in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200705-664OC

21 January 2018

Effects of salmeterol on arterial oxyhemoglobin saturations in patients with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200705-664OC

21 January 2018

Maintenance azithromycin treatment in pediatric patients with cystic fibrosis: long-term outcomes related to macrolide resistance and pulmonary function.

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200705-664OC

21 January 2018

RhDNase before airway clearance therapy improves airway patency in children with CF.

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200705-664OC

21 January 2018

A crossover, randomized, controlled trial of dornase alfa before versus after physiotherapy in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200705-664OC

21 January 2018

Microbiological and immunologic considerations with aerosolized drug delivery

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200705-664OC

21 January 2018

Pharmacokinetics of inhaled drugs

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200705-664OC

21 January 2018

Safety of repeated intermittent courses of aerosolized recombinant human deoxyribonuclease in patients with cystic fibrosis.

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200705-664OC

21 January 2018

Multicenter, open-label study of recombinant human DNase in cystic fibrosis patients with moderate lung disease. DNase International Study Group

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200705-664OC

21 January 2018

Effect of rhDNase on lung function and quality of life in adult cystic fibrosis patients

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200705-664OC

21 January 2018

DNase in stable cystic fibrosis infants: a pilot study

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200705-664OC

21 January 2018

High-dose oral N-acetylcysteine, a glutathione prodrug, modulates inflammation in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200705-664OC

21 January 2018

Controlled Trial of Inhaled Budesonide in Patients with Cystic Fibrosis and Chronic BronchopulmonaryPseudomonas aeruginosaInfection

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200705-664OC

21 January 2018

Multicenter Randomized Controlled Trial of Withdrawal of Inhaled Corticosteroids in Cystic Fibrosis

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200705-664OC

21 January 2018

Eicosapentaenoic acid in cystic fibrosis: evidence of a pathogenetic role for leukotriene B4

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200705-664OC

21 January 2018

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36924692&oldid=1514931452"